Clinical Trials Browser

Phase 1 × Laryngeal Diseases × pembrolizumab × Clear all

NCT02586207 2025-10-07

Pembrolizumab in Combination With CRT for LA-SCCHN

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Diseases, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms